CXC family of chemokines as prognostic or predictive biomarkers and possible drug targets in colorectal cancer.

ABSTRACT: Colorectal cancer (CRC) is the third most common cancer in men and the second most common cancer in women, worldwide. In the early stages of the disease, biomarkers predicting early relapse would improve survival rates. In metastatic patients, the use of predictive biomarkers could potentially result in more personalized treatments and better outcomes. The CXC family of chemokines (CXCL1 to 17) are small (8 to 10 kDa) secreted proteins that attract neutrophils and lymphocytes. These chemokines signal through chemokine receptors (CXCR) 1 to 8. Several studies have reported that these chemokines and receptors have a role in either the promotion or inhibition of cancer, depending on their capacity to suppress or stimulate the action of the immune system, respectively. In general terms, activa

SUBMITTER: Cabrero-de Las Heras S 

PROVIDER: S-EPMC6235799 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature